Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genelabs Technologies (NasdaqNM:GNLB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 21Price hit new 52-week low ($1.25)
Aug 13Earnings Announcement
Location
505 Penobscot Drive
Redwood City, CA 94063
Phone: (650) 369-9500
Fax: (650) 368-0709
Email: investorinfo@genelabs.com
Employees (last reported count): 90
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 21%
·Over the last 6 months:
 · one insider buy; 15.0K shares (0.1% of insider shares)
·Institutional: 18% (23% of float)
(63 institutions)
·Net Inst. Buying: 2.48M shares (+21.29%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genelabs Technologies, Inc. is a biopharmaceutical company focused on discovering and developing pharmaceutical products. The Company has a near-term drug candidate, Aslera, for which the United States Food and Drug Administration (FDA) is reviewing its marketing application. Aslera is a potential new treatment for systemic lupus erythematosus (lupus). In the longer term, the Company's DNA-binding drug discovery program may have the potential to create a new class of pharmaceutical products that directly target DNA. In 2000, Genelabs submitted a New Drug Application for Aslera, as a treatment for lupus, to the FDA. Lupus is a life-long autoimmune disease that causes the immune system to attack the body's own tissues and organs. The Company expects to receive a decision from the FDA on approval status by mid-year 2001. Genelabs intends to fund the discovery and development of future products from royalties received on sales of Aslera, if approved by the FDA.
More from Market Guide: Expanded Business Description

Financial Summary
Genelabs, a biopharmaceutical company, focuses its research on the discovery of small molecule drugs that function by binding to DNA to regulate gene expression or inactive pathogens. For the six months ended 6/30/01, revenues fell 29% to $2.6 million. Net loss rose 3% to $6.5 million. Revenues reflect the completion of the U.S. Defense Advanced Research Projects Agency grant. Higher loss reflects preparation costs for the potential commercial introduction of Aslera.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Irene Chow, Ph.D., 62
Chairman, CEO
$502K
James Smith, 42
Pres, Director
298K
Matthew Loar, 38
VP- Fin.
199K
Heather Keller, 35
VP, Gen. Counsel, Sec.
202K
Lynn Hughes, 45
VP of HR and Corp. Services
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GNLBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Aug-2001
$1.25 
Recent Price$1.38 
52-Week High
on 29-Jan-2001
$8.875
Beta0.41 
Daily Volume (3-month avg)346.7K
Daily Volume (10-day avg)78.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-67.8%
52-Week Change
relative to S&P500
-56.8%
Share-Related Items
Market Capitalization$68.6M
Shares Outstanding49.7M
Float39.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.36 
Earnings (ttm)-$0.26 
Earnings (mrq)-$0.07 
Sales (ttm)$0.13 
Cash (mrq)$0.54 
Valuation Ratios
Price/Book (mrq)3.78 
Price/EarningsN/A 
Price/Sales (ttm)10.92 
Income Statements
Sales (ttm)$6.04M
EBITDA (ttm)-$13.6M
Income available to common (ttm)-$12.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-53.46%
Return on Equity (ttm)-93.54%
Financial Strength
Current Ratio (mrq)4.87 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$26.7M
Short Interest
As of 8-Aug-2001
Shares Short403.0K
Percent of Float1.0%
Shares Short
(Prior Month)
1.46M
Short Ratio2.90 
Daily Volume139.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.